Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Finished

HOMEOBRAIN Homeoproteins as novel therapies for neurodegenerative diseases

Coordinator
Brainever, France
Runs
1 November 2022 to 31 October 2024
Status
Finished
EU funding
€2.5m
Total cost
€5.5m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190105256

What the project is doing

In the project's own words, from its summary on CORDIS.

With the ageing of the population, neurodegenerative diseases will be a huge societal, health and economic problem. There are no effective solutions that can stop the progression of these devastating diseases. At BrainEver we are developing a groundbreaking platform to treat neurodegenerative diseases based on a family of transcription factors called Homeoproteins (HPs). Homeoproteins are endogenous proteins expressed in diverse neuronal types, where they regulate age-dependent mechanisms related to neurodegeneration.

When homeoproteins are injected into the central nervous system of animals with disease, neuronal survival and function is restored, halting degeneration. This suggests a huge potential as therapies for neurodegenerative diseases. In this project, we aim to develop and clinically validate a revolutionary therapy using the homeoprotein Engrailed-1, to treat patients with Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s Disease (PD).

Topics

Who is involved

OrganisationCityCountryRole
BraineverParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI